Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Extension Study of the Long-term Safety, Tolerability and Efficacy of Drisapersen in US and Canadian Subjects With Duchenne Muscular Dystrophy.

NCT01803412 is registered in ClinicalTrials.gov with BioMarin Pharmaceutical as lead sponsor.

NCT NCT01803412
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01803412 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Extension Study of the Long-term Safety, Tolerability and Efficacy of Drisapersen in US and Canadian Subjects With Duchenne Muscular Dystrophy.
Lead sponsor
BioMarin Pharmaceutical
Phase
Phase 3
Overall status
Terminated
Start date
May 1, 2013
Completion date
October 1, 2016
Enrollment
53 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

muscular dystrophies